首页> 外文OA文献 >(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.
【2h】

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.

机译:(S)-乳糖酰胺对CRMP2磷酸化的抑制作用通过星座药理学鉴定的不同类别的感觉神经元减少了术后和神经性疼痛行为。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca influx with a low micromolar IC50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
机译:慢性疼痛影响着数百万人的生活。当前的治疗具有有害的副作用。我们已经针对蛋白质相互作用提出了一种策略,该策略调节N型电压门控钙(CaV2.2)通道,作为直接通道阻滞的替代方法。与轴突胶原蛋白介导蛋白2(CRMP2)脱钩的CaV2.2相互作用的肽具有抗伤害感受性,对记忆,抑郁和奖赏/成瘾没有影响。在寻找可以概括CaV2.2-CRMP2相互作用的非耦合小分子的研究中,确定了(S)-乳糖酰胺[(S)-LCM],这是美国食品药品监督管理局批准的抗癫痫药(R)-乳糖酰胺[ (R)-LCM,Vimpat]。我们显示,(S)-LCM,而不是(R)-LCM,抑制由细胞周期蛋白依赖性激酶5(驱动感觉神经元中CaV2.2活性所必需的一步)的CRMP2磷酸化。 (S)-乳糖酰胺以低微摩尔IC50抑制去极化诱导的Ca内流。电压钳电生理实验表明,急性应用(S)-LCM后,感觉神经元的Ca电流相应降低。使用星座药理学,一种最近描述的用于神经元功能指纹的高含量表型筛选平台,该平台使用亚型选择性药理剂阐明定义特定细胞类型的关键信号蛋白的细胞特异性组合(星座),我们研究了(S)- LCM优先作用于某些类型的神经元。 (S)-lacosamide减少了对芥末油反应的背根神经节神经元,并增加了对薄荷醇的反应细胞数量。最后,(S)-LCM在术后疼痛模型和2种神经性疼痛模型中逆转了热超敏反应和机械性异常性疼痛。因此,使用(S)-LCM抑制CRMP2磷酸化是一种新颖且有效的治疗疼痛的策略,该方法通过针对特定的感觉神经元群体起作用。

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号